Ovid Therapeutics Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
OVID$2.850.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| (in thousands, except share and per share data) | For The Three Months EndedJune 30, 2026 | For The Three Months EndedJune 30, 2025 | For The Six Months EndedJune 30, 2026 | For The Six Months EndedJune 30, 2025 |
|---|---|---|---|---|
| Revenue: | ||||
| License and other revenue | $733 | $6,272 | $733 | $6,402 |
| Total revenue | 733 | 6,272 | 733 | 6,402 |
| Operating expenses: | ||||
| Research and development | 9,957 | 6,465 | 21,137 | 13,123 |
| General and administrative | 6,474 | 4,880 | 13,138 | 10,902 |
| Total operating expenses | 16,431 | 11,345 | 34,275 | 24,025 |
| Loss from operations | (15,698) | (5,073) | (33,542) | (17,623) |
| Other income (expense), net | 689 | 389 | 1,546 | 2,704 |
| Loss before provision for income taxes | (15,009) | (4,684) | (31,996) | (14,919) |
| Provision for income taxes | — | — | — | — |
| Net loss | $(15,009) | $(4,684) | $(31,996) | $(14,919) |
| Net loss per share of Series A preferred stock, basic and diluted | $— | $(64.73) | $— | $(206.27) |
| Weighted-average Series A preferred stock shares outstanding, basic and diluted | — | 1,250 | — | 1,250 |
| Net loss per share of common stock, basic and diluted | $(0.08) | $(0.06) | $(0.19) | $(0.21) |
| Weighted-average common stock shares outstanding, basic and diluted | 197,453,293 | 71,109,514 | 166,674,573 | 71,077,747 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.